Objective: To evaluate the point prevalence of proteinuria in dogs presenting to the University of Georgia Oncology Service for the first time.
INTRODUCTION
Proteinuria has been identified as a marker of renal and extrarenal disease and may also be a mediator of renal compromise. In dog and cats, persistent renal proteinuria has been associated with several negative clinical outcomes including increased risk of uraemic crisis, renal disease progression and death (Jacob et al. 2005 , Syme et al. 2006 , Wehner et al. 2008 , Klosterman et al. 2011 , Chakrabarti et al. 2012 . Magnitude and persistence of proteinuria often dictate when monitoring versus treatment is recommended. In 2004, the American College of Veterinary Internal Medicine (ACVIM) Consensus Statement was published summarising guidelines for the assessment and management of proteinuria in dogs and cats (Lees et al. 2005) .
Neoplasia is one of several known causes of proteinuria in dogs. Potential factors contributing to the development of proteinuria in dogs with cancer include decreased renal blood flow, injury induced by products of the tumour cells and deposition of antigen-antibody immune complexes (Jhaveri et al. 2013 , Crivellenti et al. 2016 . One study has suggested that dogs with lymphoma have a more variable urine protein:urine creatinine (UPC) magnitude compared to dogs with other systemic diseases (Wehner et al. 2008) . Also, it has been demonstrated that dogs with lymphoma are more likely to be proteinuric than age-matched controls (Di Bella et al. 2013) , as is the case in dogs with mammary carcinoma (Crivellenti et al. 2016) . Furthermore, preoperative proteinuria has been identified as a negative prognostic factor in dogs with appendicular osteosarcoma (Saam et al. 2011) .
At our institution, an overall clinical impression has been that the majority of dogs (>50%) presenting to the oncology service have proteinuria, yet to our knowledge, the accuracy of this assessment and the degree of proteinuria seen in dogs with a variety of cancers has not previously been reported.
The objectives of this study were to estimate the point prevalence and severity of proteinuria in dogs newly presenting to a referral oncology service and to correlate the presence of proteinuria with comorbid renal disease and/or hypertension.
METHODS
This study was reviewed and approved by the University of Georgia-Veterinary Teaching Hospital (University of Georgia-VTH) Clinical Research Committee for client-owned animals (approval date: February 18, 2016). Written and signed informed consent was collected from each owner at the time of study enrolment. Client-owned dogs presented to the University of Georgia Veterinary Teaching Hospital (University of Georgia-VTH) Oncology Service for their first referral examination between April 1, 2016 and August 1, 2016 were eligible for enrolment in this prospective study. The number of dogs enrolled was limited by study funding and sample collection costs. Dogs were considered for inclusion if they had a confirmed or suspected diagnosis of neoplasia but data obtained from dogs referred with a suspected diagnosis of neoplasia that was not confirmed during the initial study period were subsequently excluded from analysis. Dogs with suspected or confirmed lower urinary tract neoplasia were excluded due to concerns of tumour seeding during routine cystocentesis and the likelihood of postrenal proteinuria secondary to local haemorrhage, secondary inflammation or neoplastic cellular debris. In addition, if the attending clinician perceived that cystocentesis could not be performed safely without adverse risk to the patient (i.e. the dog was fractious, severely thrombocytopenic, etc.), then that individual dog was deemed ineligible. Previous cancer treatments including surgery, radiation therapy, chemotherapy and/or immunotherapy were permitted as long as the treatments (excluding surgery) had been performed somewhere other than the University of Georgia-VTH.
Patient signalment, body weight and clinical history (including medication and travel histories) were recorded. Each dog's cancer diagnosis was also documented along with the date of diagnosis and location of the cancer. Routine physical examinations, including retinal examinations, were performed on all dogs. Indirect systolic blood pressure (SBP) measurements were obtained from all dogs following ACVIM hypertension consensus statement guidelines (Brown et al. 2007 ). Blood pressure cuff and limb used were recorded. At least three consecutive readings were taken using a Doppler (Vmed Vet-Dop2, Vmed Technology) unit and the mean of the blood pressure readings was recorded for each dog. Hypertension was defined as mean SBP ≥160 mmHg.
Peripheral blood was collected from the jugular vein of each dog, and spun packed cell volume (PCV), total solids (TS) and NOVA (Nova Stat Profile pHOx Ultra, Nova Biomedical) blood chemistry performed. Total solids were assessed manually using a refractometer (JorVet Clinical Refractometer, Jorgansen Laboratory, Inc.). With ultrasound guidance, urine was collected by cystocentesis and submitted for routine urinalysis (UA) and UPC. Urine samples from all dogs were saved for aerobic culture and refrigerated for no longer than 24 hours.
Using the International Renal Interest Society substage guidelines for at-risk to diseased patients, non-proteinuric, borderline proteinuria and overt proteinuria were defined as UPC <0·2, ≥0·2 but <0·5 and ≥0·5, respectively. Aerobic urine culture was performed in dogs with lower urinary tract clinical signs reported by the owner, in dogs with bacteriuria or an active sediment seen on UA and/or in dogs documented to have overt proteinuria. All urine cultures were performed by the same laboratory (University of Georgia Veterinary Diagnostic Laboratory). Active sediment was defined as white blood cells >5 per high power field (hpf ) with or without haematuria (>5 red blood cells per hpf ) or granular casts. Dogs with borderline or overt proteinuria but with inactive sediments and an absence of lower urinary tract clinical signs were recommended to have a repeat UPC 2 to 4 weeks after the initial presentation but these data were not collected as part of this study.
Statistical analysis
A single urine sample was collected from each dog at study enrolment to determine the presence and degree of proteinuria. The point prevalence of proteinuria was calculated by dividing the portion of non-proteinuric, borderline proteinuric and overtly proteinuric patients by the total patient population then multiplying by 100 to report as a percentage.
Descriptive statistics, including median value and range were determined for dog age, UPC results, time from diagnosis to presentation and cancer treatment and drug dosages and duration of administration.
RESULTS
Sixty-three dogs were screened for enrolment in this study. Three were subsequently excluded from data collection because a definitive cancer diagnosis was not confirmed cytologically or histologically during the study period.
Sixty dogs met the enrolment criteria. Of these, there were 31 neutered males, 28 spayed females and 1 intact female. Breeds included mixed breed (n=18), boxer (n=7), Labrador retriever (n=5), dachshund (n=4), poodle (n=2), Chihuahua (n=2), Weimaraner (n=2), Staffordshire terrier (n=2), golden retriever (n=2) and one each of Maltese, Scottish terrier, pug, Jack Russell terrier, English setter, cocker spaniel, great Dane, German shorthaired pointer, greyhound, rottweiler, springer spaniel, Shetland sheepdog, Italian greyhound, border collie, beagle and Yorkshire terrier. The median age at initial presentation was 9 years (range: 3 to 15 years) and the median body weight was 24·5 kg (range: 1·9 to 42·6 kg).
Sixty-one cancers were diagnosed in 60 dogs, with one dog having confirmed thyroid carcinoma and soft tissue sarcoma at the time of enrolment. Cutaneous mast cell tumour (n=15; 25%) and multi-centric high-grade lymphoma (n=8, 13%) were the most common diagnoses. Other common diagnoses included squamous cell carcinoma (n=6; 9·8%) and soft tissue sarcoma (n=5; 8·2%). Diagnoses and number of cases per University of Georgia-VTH diagnosis are summarised in Table 1. Median time from cancer diagnosis to presentation was 24 days (range: 0 to 716 days). Three subpopulations of dogs were identified, those naïve to any cancer therapy (n=35), those previously treated surgically (n=17) and those previously treated with chemotherapy (n=8). Median time from cancer diagnosis to presentation at University of Georgia-VTH within the treatment naïve population was 15 days (range: 0 to 151 days). Of the dogs treated surgically, 11 surgeries were performed by the referring veterinarian and six by the University of Georgia soft tissue surgery service. Six had complete excision and 11 had incomplete excision defined as tumour cells at the surgical margins. Median time from surgery to study enrolment for these 17 dogs was 25 days (range: 13 to 505 days). Eight dogs (13·3%) had received chemotherapy at private referral centres prior to enrolment and were presented to University of Georgia-VTH for a second opinion. Of these, seven had lymphoma and were all treated with CHOP (Cytoxan, Hydroxydaunorubicin, Oncovin, Prednisone)-based protocols (vincristine, cyclophosphamide, doxorubicin and prednisone). Of the CHOP-treated dogs, two were subsequently treated with lomustine and l-asparaginase, and one was subsequently treated with lomustine and l-asparaginase followed by dacarbazine. The eighth dog had multiple myeloma and was treated for 6 months with melphalan and prednisone, although treatment had been discontinued for approximately 1 year before presentation to University of Georgia-VTH. All dogs that had received chemotherapy before presentation had progressive, measurable disease at the time of study enrolment. For this subset of dogs, median times from diagnosis to study enrolment and from last treatment to study enrolment were 101 days (range: 51 to 716 days) and 18 days (range: 10 to 38 days), respectively.
Twenty-nine (48·3%) dogs were non-proteinuric, 22 (36·7%) borderline proteinuric and nine (15%) overtly proteinuric (Table 2) . For all dogs, the median UPC was 0·2 (mean 0·59, range: 0·05 to 9·88). Aerobic urine cultures were performed in two non-proteinuric dogs because bacteria were reported on UA; cultures were positive in both dogs. Urine cultures were performed in two borderline proteinuric dogs; reasons for culture were presence of an active sediment in one and polyuria reported by the owner in the other. Urine culture was negative in both dogs. In accordance with the study protocol, urine culture was performed in eight overtly proteinuric dogs and was negative in all. Due to clinician oversight, one dog (UPC=0·64) did not have a culture submitted, despite UPC ≥0·5.
Only two dogs in the study had a UPC ≥2·0; these were 8·41 and 9·88, respectively. Both were initiated on treatment with benazepril. One dog (UPC=9·88) was also begun on a renal diet at the time of diagnosis. Fish oil supplementation was avoided in this patient due to the start of radiation therapy and clinician opinion of a protective effect against radiation-induced damage. The UPC remained clinically static from 9·88 to 6·0 despite treatment. The UPC of the second dog (UPC=8·41) was not rechecked due to rapid cancer progression and subsequent failure to return for follow-up. Fish oils and diet change were not discussed in this case prior to the patient's disease progression.
Hypertension was diagnosed in 18 (30%) dogs, with a mean SBP in this population of 193·42 mmHg (range: 160 to 300 mmHg). Of these, six were non-proteinuric, nine had border- Biochemical abnormalities were noted in 10 dogs but none were azotaemic -blood urea nitrogen and serum creatinine levels were within reference intervals (7·5 to 30 mg/dL and 0·7 to 1·4 mg/dL, respectively). Nine dogs had mild to moderate hyperlactaemia (range: 2·7 to 7·4; reference interval: <2·5 mmol/L) and one dog was hypoglycaemic (59 mg/dL, reference interval: 80 to 120 mg/dL). Mean urine specific gravity was 1·033 (median 1·034, range: 1·013 to 1·056). Mean PCV was 45% (median 46%, range: 29 to 60%) and mean TS was 7·18 (median 7·0, range: 5·2 to 8·8).
Concomitant medications were evaluated in attempt to identify exposure to drugs known to cause proteinuria. Eight dogs were receiving mean dosage of 0·78 mg/kg/day corticosteroids (median 0·85 mg/kg/day, range: 0·21 to 1·45 mg/kg/day) for a mean duration of 44 days (median: 27 days, range: 3 to 151 days). Of these, three were non-proteinuric, three were borderline proteinuric and two were overtly proteinuric (UPC=8·41, UPC=1·68, [ Table 2 ]). One overtly proteinuric dog had been on prednisone 151 days (UPC=1·68) while the second dog (UPC=8·41) had been on prednisone for 36 days. The borderline proteinuric dogs had been on prednisone for 16, 51 and 71 days. None of the dogs were on, or had ever received, toceranib. Aside from flea, tick and heartworm preventatives, reported use of concomitant medications was uncommon, and included nonsteroidal anti-inflammatories (NSAIDs; n=2), tramadol (n=2), gabapentin (n=21), diphenhydramine (n=1), maropitant (n=1) and metronidazole (n=1). Use of heartworm preventative was not reported in 33 dogs (55%), and heartworm status was not assessed.
DISCUSSION
Proteinuria was detected in over half (51·6%) of dogs at the time of their first presentation to the University of Georgia Oncology Service during the study period. The majority of those had borderline proteinuria (36·7%), whereas only 16·6% were overtly proteinuric. Proteinuria requiring intervention (i.e. those with UPC ≥2·0) was seen in only 3% of the total population, with the majority (70%) of overtly proteinuric dogs having urinary protein loss <1·2. Concurrent renal azotaemia was not seen in any of the dogs. Thirty percent of dogs were hypertensive, the majority of which (83·3%) were non-or borderline proteinuric. Our results suggest that while many dogs with cancer have proteinuria, few have proteinuria requiring therapeutic intervention at the time of identification. Nonetheless, screening and serial monitoring when proteinuria is detected are warranted.
Reportedly 25 to 31% of seemingly healthy middle age to geriatric dogs and, cats (Paepe et al. 2013 are persistently proteinuric, (borderline 14 to 25%, overt 2 to 13%), suggesting that measurement of proteinuria should be part of geriatric health screening. Cancer, a recognised cause of proteinuria, most commonly occurs in the aged population, further supports the importance of this diagnostic test in geriatric patients. Specific to dogs, proteinuria has been associated with mammary carcinoma, osteosarcoma and lymphoma (Pressler et al. 2003 , Saam et al. 2011 , Di Bella et al. 2013 . Although it would have been interesting to correlate the magnitude of persistent proteinuria with specific cancer diagnoses and even cancer stage, this was not attempted in the present study due to the large number of confounding patient variables and the limited number of cancer diagnoses other than cutaneous mast cell tumour and lymphoma. Larger additional studies are needed to evaluate the role of disease stage and tumour subtype on proteinuria development.
Infectious diseases such as parasitic, viral and bacterial diseases -including tick-borne diseases -have been identified as causes as proteinuria in dogs. Likewise, systemic inflammatory diseases, including immune-mediated haemolytic anaemia, diabetes mellitus and acute pancreatitis also have causal relationships with proteinuria (Pressler et al. 2003 , Whittemor et al. 2006 , Vaden et al. 2010 , Schaefer et al. 2011 , Harley & Langston 2012 . In canine cancer patients with comorbidities resulting in systemic inflammation, elucidation of the exact cause and the sequence of events in the development of proteinuria proves challenging. In our study, heartworm and infectious disease agent testing was not performed, making it difficult to completely rule out non-neoplastic diseases as contributory. Additionally, the warmer seasonal time frame of the study may have increased the risk of infectious disease exposure in the included dogs. Despite the absence of supportive physical exam and laboratory data abnormalities, the potential contributory role of non-or subclinical infectious and inflammatory diseases cannot be ruled out in this older subset of dogs without more exhaustive testing.
Medications, most notably corticosteroids and toceranib phosphate, have been shown to induce proteinuria in dogs (Wetzels et al. 1986 , Waters et al. 1997 , Tjostheim et al. 2016 . While none of the dogs in this study had previously received toceranib, eight were on prednisone at the time of their initial proteinuria screening. Of these, five were proteinuric including three with borderline proteinuria and two with overt proteinuria. Interestingly, the dog with the UPC of 8·41, the second highest in the study, had been on a longest dose of 0·98 mg/kg/day prednisone (151 days). Although noteworthy, elucidation of the role of corticosteroids and even previous chemotherapy in the development of proteinuria in this patient population was beyond the scope of this study.
Another cause of proteinuria in dogs is systemic hypertension (Finco 2004 , Wehner et al. 2008 , Segev 2010 . Eighteen dogs (30%) in our study had hypertension, 12 (67%) of which were proteinuric. Only one dog had evidence of end-organ injury with retinal haemorrhage identified. While the "white coat effect" or stress-induced hypertension could have interfered with our ability to accurately measure blood pressure in these dogs, all dogs were acclimated to the environment to limit this effect. Though difficult to discern the role of hypertension in the proteinuric dogs, the large percentage with both hypertension and proteinuria supports a possible causal relationship. Furthermore, as renal disease is a known cause for secondary hypertension, which came first may be an equally important question. Regardless, as in any proteinuric dog, assessment of blood pressure in cancer patients with identified proteinuria seems prudent.
Finally, acute and chronic renal disease has been associated with proteinuria in dogs, and chronic renal disease specifically is a comorbidity seen in geriatric dogs. None of the dogs in this study were azotaemic, though some had a urine specific gravity in the minimally concentrated range. The International Renal Interest Society classifies non-azotaemic proteinuria as stage 1 chronic kidney disease. Therefore, it seems plausible that most canine cancer patients with proteinuria fall into this group.
A primary limitation of this study was that UPC determination was only completed for one point in time and significant day-to-day variation in UPC in dogs with nephropathy has been documented (Nabity et al. 2007 ). While some dogs had recheck examinations which facilitated repeat urine testing, collection of this data was not required as part of this study.
The majority of the dogs had borderline proteinuria but its clinical significance was beyond the scope of this study. With that being said, it must be noted that a diagnosis of proteinuria should prompt further testing to help identify potential underlying conditions such as hypertension. Furthermore, as it has been established that cancer is an independent cause of proteinuria, cancer screening may be prudent in cases where an underlying cause cannot be identified. Future studies may help answer these questions.
In conclusion, proteinuria is a common biochemical abnormality found in dogs with cancer presenting to a referral oncology service for their initial evaluation. Based on our results, the degree of proteinuria is generally mild, typically requiring monitoring rather than immediate intervention. Our results further support screening for proteinuria as part of the diagnostic assessment of the canine cancer patient.
